ArticleiLIVER2024

Analysis of efficacy and safety for the combination of regorafenib and PD-1 inhibitor in advanced hepatocellular carcinoma: A real-world clinical study.

Zhongchao Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.